Change over period
From:
To:
Zoom:
- 1Y
- 3Y
- 5Y
- 10Y
- 15Y
- 20Y
- Max
Hepion Pharmaceuticals Inc
NASDAQ HEPA
Data sourced from
and
and
Hepion Pharmaceuticals Inc Total Liabilities to Total Assets Ratio 1 year YoY Change (%) for the quarter ending March 31, 2024: 246.57%
Hepion Pharmaceuticals Inc Total Liabilities to Total Assets Ratio 1 year YoY Change (%) is 246.57% for the quarter ending March 31, 2024, a 256.64% change year over year. The total liabilities to total assets ratio measures the proportion of total liabilities to total assets. It is calculated by dividing the total liabilities by the total assets. This ratio provides insights into the company's financial leverage and the proportion of its assets financed by liabilities. A higher ratio indicates a higher level of financial risk and reliance on liabilities for asset acquisition. The measure "Change (%)" refers to the percentage change in the value of a financial metric between two time points. This measure provides a relative perspective on the magnitude of change.
-
Hepion Pharmaceuticals Inc Total Liabilities to Total Assets Ratio for the quarter ending March 31, 2023 was 0.17, a 69.14% change year over year.
-
Hepion Pharmaceuticals Inc Total Liabilities to Total Assets Ratio for the quarter ending March 31, 2022 was 0.10, a 104.09% change year over year.
-
Hepion Pharmaceuticals Inc Total Liabilities to Total Assets Ratio for the quarter ending March 31, 2021 was 0.05, a -75.98% change year over year.
-
Hepion Pharmaceuticals Inc Total Liabilities to Total Assets Ratio for the quarter ending March 31, 2020 was 0.21, a -77.35% change year over year.
Don’t Miss A Beat
Looking to stay ahead of the competition and stay informed? Receive your daily dose of market news, trends, and analysis to kickstart your day and stay up-to-date.
NASDAQ: HEPA
| CEO | Dr. Robert T. Foster B.Sc., BSc (Pharm), Ph.D., Pharm.D. |
| IPO Date | Feb. 11, 2014 |
| Location | United States |
| Headquarters | 399 Thornall Street, Edison, NJ, United States, 08837 |
| Employees | 22 |
| Sector | Healthcare |
| Industry | Biotechnology |
Description
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor is in Phase 2b clinical trial to target multiple pathologic pathways involved in the progression of liver disease and treat non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.
Key trends
Similar companies
AVROBIO Inc
NA
NA
StockViz Staff
September 20, 2024
Any question? Send us an email